A recent study combined analysis of a patient's tumor genome and transcriptome sequences to guide treatment of tongue adenocarcinoma with Pfizer's Sutent (sunitinib) and Bayer's Nexavar (sorafenib).
The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.
US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.
Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.
In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.
